Faculty Viewpoints

Objections from business leaders played a key role in pushing the Trump Administration to reverse course on recently announced “reciprocal” tariffs, according to Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Stephen Henriques. It’s a win for business, they write, but the business community remains concerned about uncertainty around economic policy.

Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian write that the administration’s unpredictable approach is bringing new corporate initiatives to a standstill and pushing the economy toward recession.

The scale of cuts to the federal healthcare workforce is now coming into focus. Dr. Howard Forman explains the potential life-and-death consequences of cuts to key programs and the departure of longtime leaders. ‌

Yale SOM’s Stefano Giglio, an expert on climate finance, explains what green investing can and can’t do to help speed the transition to a post-carbon economy.

Amid warming relations with Washington, Vladimir Putin is floating new opportunities for Western companies in Russia. But Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian write that business leaders are reluctant to reengage in a dangerous setting and a faltering economy.

Yale SOM leadership expert Jeffrey Sonnenfeld writes that rather than zeroing in on waste and bureaucracy, the Department of Government Efficiency is driving out thousands of critical workers.

Yale SOM’s Jeffrey Sonnenfeld and co-authors Stephen Henriques and Steven Tian write that while there are legitimate reasons for some tariffs, the president’s arbitrary approach is worrying allies and unsettling markets.

Leadership expert Jeffrey Sonnenfeld and co-author Steven Tian look across history for examples of pitfalls that could lie ahead for Elon Musk and Donald Trump.

Congressional Republicans are looking to make deep budget cuts, and Medicaid spending is a target. Yale SOM’s Dr. Howard Forman says that large-scale reductions in the program would hit the poorest states and the most vulnerable Americans especially hard. ‌‌

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.